Is QGEN a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

523 people get QGEN articles and Market Currents by email alert.

Get email alerts on QGEN »

FOCUS | PRO | RELATED | TRANSCRIPTS | NEWS & PR

Qiagen: Limited Visibility On When Improvement Will Materialize
ITT Investment Research • Thu, May 9
Qiagen: Downside Priced In, CDx And Automation Upside, Undervalued Compared To Peers
Dave Westenberg • Sat, Sep 29, 2012
Qiagen: FDA Submissions May Make This Bottom Bouncer More Appealing
M. E. Garza • Mon, Aug 8, 2011 • 1 Comment
Qiagen to Collaborate on Food Safety Tests
ChinaBio Today • Sun, Sep 28, 2008
Qiagen Aims to Provide Services 'Any Time, Any Place'
ChinaBio Today • Mon, Feb 25, 2008
Qiagen Reports Positive Trial for HPV Diagnostic Test in China
ChinaBio Today • Fri, Nov 9, 2007 • 1 Comment

To learn more about Seeking Alpha Pro, click here.

China Biotech In Review: Valeant Pharma Gains Sales Foothold In China With Bausch & Lomb Buy
ChinaBio Today • Sun, Jun 2
Diabetes And Oncology Might Cushion Eli Lilly's Fall Off A Patent Cliff
Cory Renauer • Fri, May 24 • 1 Comment
6 Ways You Can Profit From Molecular Diagnostics
Cory Renauer • Wed, May 22 • 15 Comments
Why Royalty And Milestone Partnership Dynamics Imply Trovagene Could Triple
Logical Assessment • Fri, May 3 • 6 Comments
Could Enzo Biochem's Intellectual Property Lawsuits Be Worth Billions?
Glen S. Woods • Sun, Apr 28 • 6 Comments
Trovagene Advances Next-Gen Version Of Qiagen's HPV Test
Mars Report • Tue, Apr 2 • 4 Comments
Atossa Genetics: Room For Further Price Appreciation
Grant Zeng • Mon, Mar 25 • 4 Comments
LipoScience - A Small Company Targeting A Large Market
Stephen Simpson • Tue, Feb 26
Response Genetics' Competitors: Who To Watch, Who To Worry About
Bay Area Biotech • Fri, Feb 8 • 7 Comments
Halftime Report: Q4 Earnings Season
Lou Basenese • Thu, Feb 7
Week In Review: Hutchison Chi-Med Forms Drug Development JV With Nestlé
ChinaBio Today • Sun, Dec 2, 2012
Earnings Analysis: Quest Diagnostics Inc.
CapitalCube • Thu, Oct 18, 2012
China Biotech In Review: WuXi AppTec And MedImmune Start Joint Venture
ChinaBio Today • Sun, Sep 16, 2012 • 1 Comment
Earnings Analysis For Pall Corp.: Sustainable Returns Relative To Peers
CapitalCube • Fri, Sep 14, 2012
Hologic Seems A Little Underrated
Stephen Simpson • Tue, Jul 31, 2012 • 4 Comments
How Did J.P. Morgan's Recommendations Play Out?
Insider Monkey • Sat, Jul 28, 2012
Coming Wave Of Companion Diagnostics: Who's Making A Splash
Dave Westenberg • Thu, Jul 26, 2012 • 7 Comments
Top Medical Technology Stocks Most Favored By The World's Largest Fund Managers
GuruFundPicks • Thu, Jul 19, 2012 • 2 Comments
Trading Margins For Growth Isn't Going To Help Becton Dickinson
Stephen Simpson • Thu, May 3, 2012 • 2 Comments
China Biotech In Review: GSK Explores All Paths To Increase China Presence
ChinaBio Today • Sun, Mar 11, 2012

Qiagen NV Management Discusses Q1 2013 Results - Earnings Call Transcript
Tue, Apr 30
QIAGEN's CEO Discusses Q4 2012 Results - Earnings Call Transcript
Wed, Jan 30
Qiagen N.V's CEO Discusses Q3 2012 Results - Earnings Call Transcript
Mon, Nov 5, 2012
Qiagen's CEO Discusses Q2 2012 Results - Earnings Call Transcript
Wed, Jul 25, 2012
QIAGEN's CEO Discusses 1Q 2012 Results - Earnings Call Transcript
Thu, Apr 26, 2012
QIAGEN's CEO Discusses Q4 2011 Results - Earnings Call Transcript
Wed, Feb 1, 2012
QIAGEN's CEO Hosts Investor Day - Conference Call Transcript
Fri, Nov 18, 2011
QIAGEN's CEO Discusses Q3 2011 Results - Earnings Call Transcript
Thu, Nov 3, 2011 • 1 Comment
Qiagen's CEO Discusses Q2 2011 Results - Earnings Call Transcript
Tue, Jul 26, 2011
QIAGEN N.V. Q3 2007 Earnings Call Transcript
Wed, Nov 7, 2007

QIAGEN Significantly Expands its Offering of Assay Panels for Next-generation Sequencing (NGS) Complemented by Ingenuity Analysis and Interpretation Capabilities

PR Newswire (Jun 7, 2013)
QIAGEN Comments on Decision by a U.S. Reference Laboratory Customer to Consolidate Purchase of Women's Health Tests with Competitor Supplier

PR Newswire (Jun 6, 2013)
QIAGEN Expands Pipeline of Promising New Biomarkers for Development of Personalized Healthcare Companion Diagnostics

PR Newswire (May 31, 2013)
QIAGEN Posts 2012 Annual Report on Its Website

GlobeNewswire (May 15, 2013)
QIAGEN Proposes Changes to Members of Supervisory Board

PR Newswire (Apr 29, 2013)
QIAGEN Acquires Ingenuity Systems, Adding Leading Solution for Analysis and Interpretation of Complex Biological Data

PR Newswire (Apr 29, 2013)
QIAGEN Reports First Quarter 2013 Results

PR Newswire (Apr 29, 2013)
QIAGEN N.V. to Report First Quarter 2013 Results and Hold Webcast

GlobeNewswire (Apr 15, 2013)
QIAGEN Unveils Sample-to-Result Next-Generation Sequencing Workflow Designed for Clinical Research and Diagnostics

PR Newswire (Feb 20, 2013)
QIAGEN Enters Into Broad Collaboration Agreement With Lilly for the Development and Commercialization of Companion Diagnostics

PR Newswire (Feb 13, 2013)
QIAGEN's KRAS Companion Diagnostic for Colorectal Cancer Adopted by Clarient, a Leading U.S. Oncology Service Lab

PR Newswire (Jan 30, 2013)
QIAGEN Reports Fourth Quarter and Full-Year 2012 Results

PR Newswire (Jan 29, 2013)
QIAGEN N.V. to Report Fourth Quarter and Full-Year 2012 Results and Hold Webcast

GlobeNewswire (Jan 15, 2013)
QIAGEN Submits Companion Diagnostic to FDA to Guide Treatment Decisions for New Investigational Lung Cancer Compound

PR Newswire (Jan 15, 2013)
QIAGEN Adds to Pipeline of Personalized Healthcare Diagnostics Through Agreements for Promising New Biomarkers

PR Newswire (Jan 7, 2013)
QIAGEN Exceeds 2012 Goal for Placements of QIAsymphony Breakthrough Laboratory Automation System

PR Newswire (Jan 7, 2013)
QIAGEN to Present at the 31st Annual J.P. Morgan Healthcare Conference

GlobeNewswire (Jan 4, 2013)
QIAGEN Gains SFDA Approval to Market careHPV Test in China - Expanding Access to HPV Testing in Low-resource Countries

PR Newswire (Nov 28, 2012)
QIAGEN Kicks Off Next-Generation Sequencing Initiative With Launch of a Series of Consumable Products to Improve NGS Workflows

PR Newswire (Nov 5, 2012)
QIAGEN Reports Third Quarter 2012 Results

PR Newswire (Nov 4, 2012)

QGEN vs. ETF Alternatives

Company Description

Currently, there's no company description for QGEN.

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Friday, June 7, 11:35 AM Qiagen (QGEN -0.1%) says it plans to significantly expand its existing portfolio of molecular assays used in next-generation sequencing during 2013. The current portfolio of nine GeneRead DNAseq panels, launched in late 2012, will be expanded to approximately 20 during the course of 2013, giving researchers a wider range of targeted clinical sequencing for the study of cancer and other diseases. Comment! [Healthcare]
Thursday, June 6, 2:47 PM Qiagen (QGEN +0.7%) says that a U.S. reference laboratory customer of its HPV-related products used for cervical cancer screening has decided to consolidate the purchase of products used for women's health diagnostics with a competitor supplier. The company sees no need to revise its guidance for 2013 at present, noting that sales related to this development represent less than 2% of its anticipated total net sales for 2014, and that products used in HPV screening in the U.S. are projected to be less than 10% of total net sales in 2014. Comment! [Healthcare]
Friday, May 31, 11:41 AM Qiagen (QGEN -0.7%) signs two new deals, one with Columbia University, and the other with the BC Cancer Agency based out of Vancouver, Canada, which will add new biomarkers to its portfolio of potential companion diagnostics being developed to help doctors use a patient's genomic information to treat glioblastoma, lymphoma and other cancers. Comment! [Healthcare]
Tuesday, April 30, 9:10 AM Premarket gainers: HPY +10%. HTWR +9%. ANAD +9%. AVP +8%. UBS +7%. BBY +6%.
Losers: DCTH -20%. AVEO -16%. NUAN -15%. PBI -10%. MTG -8%. CNH -6%. RVBD -6%. QGEN -5%. Comment! [On the Move]
Monday, April 29, 4:21 PM Qiagen (QGEN): Q1 EPS of $0.23 in-line. Revenue of $303.6M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Monday, April 29, 12:10 AM Notable earnings after Monday’s close: ANAD, ANH, BWLD, CBL, CRK, CSE, CYH, DTLK, ESRX, GGP, HIG, HLF, HTZ, IDTI, JEC, MAS, MSTR, NEM, PCL, QGEN, RGR, RJET, RVBD, SBAC, SSW, SU, TXRH, VECO 1 Comment [Earnings]
Sunday, April 28, 5:35 PM Notable earnings after Monday’s close: ANAD, ANH, BWLD, CBL, CRK, CSE, CYH, DTLK, ESRX, GGP, HIG, HLF, HTZ, IDTI, JEC, MAS, MSTR, NEM, PCL, QGEN, RGR, RJET, RVBD, SBAC, SSW, SU, TXRH, VECO 1 Comment [Earnings]
Wednesday, February 13, 4:43 PM Building on past work, Qiagen (QGEN) enters into a collaboration agreement with Eli Lilly (LLY) for the development and commercialization of companion diagnostics for pairing with LLY's investigational and approved medicines across all therapeutic areas. Companion diagnostics unlock a patient's molecular information in order to guide treatment decisions for specific cancers or other diseases. Financial terms of the agreement aren't disclosed. Comment! [Healthcare]
Tuesday, January 29, 4:18 PM More on Qiagen (QGEN): Q4 beats across the board, led by 4% net sales growth in its Molecular Diagnostics and Applied Testing units. Growth was strong across all geographic regions; Americas +46%, Europe +9%, Asia-Pacific & Japan +19%. The company guides FY13 earnings higher, now expecting an EPS of $1.16 - $1.18 - versus the consensus of $1.15 - and revenues to grow about 5% - 6%. Comment! [Healthcare, Earnings]
Tuesday, January 29, 4:10 PM Qiagen (QGEN): Q4 EPS of $0.34 beats by $0.03. Revenue of $346.5M (+4% Y/Y) beats by $18.7M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Monday, November 5, 2012, 11:24 AM Qiagen (QGEN +1.1%) gains after its Q3 beat on all counts this morning. On paper, net earnings fell 17% Y/Y, but that number is skewed from a one-time acquisition gain, which masked a 10% rise in total revenue over the same period last year. The company has struggled in recent quarters as patients reduced their use of health-care services, but early this year the company completed a streamlining process which gave a big boost to bottom line margins. Comment! [Healthcare, Earnings, On the Move]
Monday, November 5, 2012, 5:08 AM Qiagen (QGEN): Q3 EPS of $0.26 beats by $0.02. Revenue of $304.3M (+10% Y/Y) beats by $1M. (PR) Comment! [Earnings, Healthcare]
Tuesday, July 24, 2012, 5:38 PM More on Qiagen (QGEN): Q2 earnings were nearly flat as the provider of medical-testing technologies revenue growth was masked by higher acquisition-related costs and other expenses. The company raises its FY12 EPS estimate to $1.04 - $1.06 on sales growth of 8% - 9%, versus its prior estimate of $1.03 - $1.05 on sales growth of 6% - 8%, and unveils a stock buyback of up to $100M. Comment! [Healthcare, Earnings]
Tuesday, July 24, 2012, 5:13 PM Qiagen (QGEN): Q2 EPS of $0.25 in-line. Revenue of $307.2M (+8.9% Y/Y). (PR) Comment! [Earnings, Healthcare]
Friday, July 6, 2012, 4:38 PM QIAGEN (QGEN) says it's received FDA approval to market its therascreen KRAS test to provide guidance on the use of Erbitux as a treatment in patients with metastatic colorectal cancer. Comment! [Healthcare]
Monday, July 2, 2012, 3:23 PM Qiagen (QGEN +1.7%) trades up after Goldman upgraded the shares to Neutral today, based on reduced risk to 2012 estimates and an M&A premium due to the scarcity value of its assets. Comment! [On the Move, Healthcare]

ltfinger
Returning Upgrades (4/11/13): $MGA, $MIC, $MMC, $NEOG, $NUVA, $PAYX, $PBJ, $PCL, $PCRX, $PFF, $PM, $POWR, $PRGO, $PRXL, $QGEN, $RDEN
Apr 12, 10:33 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Chuck Carnevale
$QGEN - Is $QGEN a good buy? See 15-year earnings & price correlated F.A.S.T. Graphs: http://bit.ly/sX6C9x
11/30/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Justin M. Hall
8/6/11 12A ET: (ONXX, ITMN, GSK, QGEN, GPRO) BIOTECH CORRECTION Called in June 2011 => Were You Paying Attention? http://seekingalpha.com/p/4bsg
8/6/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Justin M. Hall
6/13/11 5:18 AM ET: BIOTECH names trading under 200 MAs that could fall further - GSK, IPXL, LIFE, QGEN, SLXP, TEVA, THRX, UTHR & WCRX.
6/13/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Dividend Sheet
15 Big Players In Biotechnology Industry ++ http://t.co/OahlkmY ++ AMGN, GILD, SNY, BIIB, LIFE, ILMN, DNDN, GSK, CEPH, SHP, QGEN, TLCR
2/3/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

AlphaLoboTrading
QGEN - 21.38 - would short the move with stops above 21.70
2/12/10
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

QGEN Qiagen N.V.

QGEN

Qiagen N.V.